Toggle navigation image image
Toggle navigation logologo
image image
  • About Inflarx
    • Leadership Team
    • Board
    • Company History
    • Vision
  • R&D
    • About Complement
    • About C5A
    • Technology
    • Pipeline
    • Clinical Development
      • Hidradenitis Suppurativa
        • Shine Study FAQ
      • ANCA-Associated Vasculitis
      • Pyoderma Gangraenosum
      • COVID-19
      • cSCC
    • Clinical Trials
    • Publications & Posters
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Share Information
    • Analyst Coverage
    • Corporate Governance
    • Annual/Extraordinary General Meetings
    • E-mail alerts
  • Career
    • Open Positions
      • Office Manager (m/w/d)
      • Controller (m/w/d)

Publications & Posters

  • Home
  • R&D
  • Publications & Posters

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Authors: Alexander P J Vlaar, Martin Witzenrath, Pieter van Paassen, Leo M A Heunks, Bruno Mourvillier, Sanne de Bruin, Endry H T Lim, Matthijs C Brouwer, Pieter R Tuinman, José F K Saraiva, Gernot Marx, Suzana M Lobo, Rodrigo Boldo, Jesus A Simon-Campos, Alexander D Cornet, Anastasia Grebenyuk, Johannes M Engelbrecht, Murimisi Mukansi, Philippe G Jorens, Robert Zerbib, Simon Rückinger, Korinna Pilz, Renfeng Guo, Diederik van de Beek*, Niels C Riedemann*, on behalf of the PANAMO study group†
Publication details: Published Online September 7, 2022. doi: 10.1016/S2213-2600(22)00297-1

read more...


Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Authors: Alexander P J Vlaar, Sanne de Bruin, Matthias Busch, Sjoerd A M E G Timmermans, Ingeborg E van Zeggeren, Rutger Koning, Liora ter Horst, Esther B Bulle, Frank E H P van Baarle, Marcel C G van de Poll, E Marleen Kemper, Iwan C C van der Horst, Marcus J Schultz, Janneke Horn, Frederique Paulus, Lieuwe D Bos, W Joost Wiersinga, Martin Witzenrath, Simon Rueckinger, Korinna Pilz, Matthijs C Brouwer, Ren-Feng Guo, Leo Heunks, Pieter van Paassen, Niels C Riedemann, Diederik van de Beek
Publication details: Published Online September 28, 2020. doi: 10.1016/ S2665-9913(20)30341-6

read more...


Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?

Authors: Kanni T, Zenker O, Habel M, Riedemann N, Giamarellos-Bourboulis EJ.
Publication details: Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16428. [Epub ahead of print]

read more...


Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application.

Authors: Sun S, Jiang Y, Wang R, Liu C, Liu X, Song N, Guo Y, Guo R, Du L, Jiang S, Li Y, Qiu Z, Zhao G, Zhou Y
Publication details: Crit Care Med. 2018 Jan 2. doi: 10.1097/CCM.0000000000002950. [Epub ahead of print]

read more...


IFX-1 blocking the anaphylatoxin C5a – an anti-inflammatory effect in patients with hidradenitis suppurativa.

Authors: Guo R, Habel M, Zenker O, Giamarellos-Bourboulis EJ, Riedemann NC
Publication details: 16th European Meeting on Complement in Human Disease (EMCHD2017), Copenhagen, Sep 2017


An open-label trial to assess the safety of IFX-1 in patients with hidradenitis suppurativa not eligible for Adalimumab.

Authors: Argyropoulou M, Kanni T, Zenker O, Riedemann NC, Giamarellos-Bourboulis EJ
Publication details: 26th European Academy of Dermatology and Venereology (EADV) Congress, Geneva, Sep 2017


Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition.

Authors: Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, Kirschfink M, Kentouche K, Guo R
Publication details: Clin Immunol. 2017 Jul;180:25-32. doi:10.1016/j.clim.2017.03.012

read more...


Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Authors: Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M
Publication details: Clin Exp Immunol. 2017 Feb;187(2):304-315. doi: 10.1111/cei.12890

read more...


The role of C5a in acute lung injury induced by highly pathogenic viral infections.

Authors: Wang R, Xiao H, Guo R, Li Y, Shen
Publication details: Emerg Microbes Infect. 2015 May;4(5):e28. doi: 10.1038/emi.2015.28

read more...


A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a.

Authors: Hünniger K, Bieber K, Martin R, Lehnert T, Figge MT, Löffler J, Guo RF, Riedemann NC, Kurzai O
Publication details: J Immunol. 2015 Feb 1;194(3):1199-210. doi: 10.4049/jimmunol.1401845

read more...


Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys.

Authors: Sun S, Zhao G, Liu C, Fan W, Zhou X, Zeng L, Guo Y, Kou Z, Yu H, Li J, Wang R, Li Y, Schneider C, Habel M, Riedemann NC, Du L, Jiang S, Guo R, Zhou Y
Publication details: Clin Infect Dis. 2015 Feb 15;60(4):586-95. doi: 10.1093/cid/ciu887

read more...


Early intra-articular complement activation in ankle fractures.

Authors: Schmal H, Salzmann GM, Niemeyer P, Langenmair E, Guo R, Schneider C, Habel M, Riedemann N
Publication details: Biomed Res Int. 2014;2014:426893. doi: 10.1155/2014/426893

read more...


Quick Links
  • Impressum
  • Privacy
  • Technology
  • News
  • Career
  • Disclaimer
  • Contact
  • Newsletter
  • Member area
Contact Jena

InflaRx N.V. / InflaRx GmbH
Winzerlaer Str. 2
07745 Jena

+49 3641 508 180

info@inflarx.de

InflaRx on Linkedin

Contact Munich

InflaRx N.V. / InflaRx GmbH
Fraunhoferstraße 22
82152 Martinsried

+49 89 414 189 78 00

info@inflarx.de

Contact Ann Arbor

InflaRx Pharmaceuticals Inc.
600 S. Wagner Rd.
Ann Arbor, MI 48103

info@inflarx.de

© Copyright 2017 All Rights Reserved.
  • Developed by Ementals